Roxanne Austin - Abbott Laboratories Independent Director

ABTT34 Stock  BRL 47.39  0.30  0.64%   

Director

Ms. Roxanne S. Austin serves as Independent Director of the Company. Ms. Austin is President and Chief Executive Officer of Austin Investment Advisors, a private investment and consulting firm, and chairs the U.S. MidMarket Investment Advisory Committee of EQT Partners. Previously, Ms. Austin also served as the President and Chief Executive Officer of Move Networks, Inc., a provider of Internet television services. Ms. Austin served as President and Chief Operating Officer of DIRECTV, Inc. Ms. Austin also served as Executive Vice President and Chief Financial Officer of Hughes Electronics Corporation and as a partner of Deloitte Touche LLP. Ms. Austin served on the Board of Directors of Telefonaktiebolaget LM Ericsson from 2008 to 2016 since 2000.
Age 58
Tenure 24 years
Phone224 667 6100
Webhttps://www.abbott.com
Austin currently serves on the Board of Directors of AbbVie Inc., Target Corporationrationrationration, and Teledyne Technologies, Inc. Through her extensive management and operating roles, including her financial roles, Ms. Austin contributes significant oversight and leadership experience, including financial expertise and knowledge of financial statements, corporate finance and accounting matters.

Abbott Laboratories Management Efficiency

The company has return on total asset (ROA) of 0.0882 % which means that it generated a profit of $0.0882 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1928 %, meaning that it generated $0.1928 on every $100 dollars invested by stockholders. Abbott Laboratories' management efficiency ratios could be used to measure how well Abbott Laboratories manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 17.3 B in total debt with debt to equity ratio (D/E) of 0.55, which is about average as compared to similar companies. Abbott Laboratories has a current ratio of 1.72, which is within standard range for the sector. Debt can assist Abbott Laboratories until it has trouble settling it off, either with new capital or with free cash flow. So, Abbott Laboratories' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Abbott Laboratories sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Abbott to invest in growth at high rates of return. When we think about Abbott Laboratories' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Stephen GirskyUnited States Steel
56
Martha KeethVerizon Communications
71
John EngelUnited States Steel
57
Eugene SperlingUnited States Steel
60
Clarence OtisVerizon Communications
63
Shellye ArchambeauVerizon Communications
56
Paul MascarenasUnited States Steel
57
John FaraciUnited States Steel
69
Kathryn TesijaVerizon Communications
56
Donald NicolaisenVerizon Communications
70
Patricia TraceyUnited States Steel
67
Richard RexachVerizon Communications
63
Richard CarrionVerizon Communications
67
Mark BertoliniVerizon Communications
62
Gregory WeaverVerizon Communications
67
Daniel SchulmanVerizon Communications
61
Murry GerberUnited States Steel
66
KarlLudwig KleyVerizon Communications
66
Dan DingesUnited States Steel
65
Patricia DennisUnited States Steel
72
Rodney SlaterVerizon Communications
64
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company was founded in 1888 and is based in North Chicago, Illinois. ABBOTT DRN operates under Medical Devices classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 109000 people. Abbott Laboratories (ABTT34) is traded on Sao Paulo Exchange in Brazil and employs 115,000 people.

Management Performance

Abbott Laboratories Leadership Team

Elected by the shareholders, the Abbott Laboratories' board of directors comprises two types of representatives: Abbott Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Abbott. The board's role is to monitor Abbott Laboratories' management team and ensure that shareholders' interests are well served. Abbott Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Abbott Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
Samuel Scott, Independent Director
Christopher Scoggins, Senior Vice President - Rapid Diagnostics
Roger Bird, Senior Vice President - U.S. Nutrition
Michael Dale, Senior Vice President - Structural Heart
Sammy Karam, Senior Vice President - Established Pharmaceuticals, Emerging Markets
Heather Mason, Senior Vice President - Abbott Diabetes Care
James Farrell, Independent Director
Phebe Novakovic, Independent Director
JeanYves Pavee, Senior Vice President - Established Pharmaceuticals, Developed Markets
Roxanne Austin, Independent Director
Stephen Fussell, Senior Vice President - Human Resources
Sally Blount, Independent Director
Daniel Starks, Independent Director
Michael Pederson, Senior Vice President - Electrophysiology and Heart Failure
Thomas Frinzi, Senior Vice President - Abbott Medical Optics
Lisa Earnhardt, Executive Vice President - Medical Devices
Alejandro Wellisch, Senior Vice President - Established Pharmaceuticals, Latin America
Robert Alpern, Independent Director
Murthy Simhambhatla, Senior Vice President - Abbott Medical Optics
Glenn Tilton, Independent Director
Darren McDew, Independent Director
Richard Ashley, Executive VP of Corporate Devel.
Michael Rousseau, President - Cardiovascular and Neuromodulation
Charles Brynelsen, Senior Vice President - Abbott Vascular
Hubert Allen, Executive Vice President, General Counsel, Secretary
Charles Foltz, Senior Vice President - Abbott Vascular
Brian Yoor, Chief Financial Officer, Executive Vice President - Finance
John Ginascol, Executive Vice President - Core Diagnostics
Jared Watkin, Senior Vice President - Diabetes Care
Brian Blaser, Executive VP of Diagnostic Products
Scott White, Senior Vice President - International Nutrition
Deepak Nath, Senior Vice President - Abbott Vascular
Jaime Contreras, Senior Vice President - Core Laboratory Diagnostics, Commercial Operations
Mary Moreland, Executive Vice President of Human Resources
Nancy McKinstry, Independent Director
Andrew Lane, Senior Vice President - Established Pharmaceuticals, Emerging Markets
Georges Vos, Senior Vice President - Established Pharmaceuticals, Emerging Markets
Thomas Freyman, Executive VP of Fin. and Admin.
Randel Woodgrift, Senior Vice President - CRM
Michelle Kumbier, Independent Director
Eric Fain, Senior Vice President Group President - Cardiovascular and Neuromodulation
John Capek, Executive Vice President - Ventures
Miles White, Chairman, CEO and Chairman of Executive Committee
Robert Ford, President, Chief Executive Officer, Chief Operating Officer, Director
Elaine Leavenworth, VP Officer
Edward Liddy, Independent Director
John Stratton, Independent Director
Joseph Manning, Senior Vice President - Abbott Nutrition International
Scott Leinenweber, Licensing Relations
James Young, VP Officer
William Osborn, Lead Independent Director
Michael Warmuth, Executive Vice President - Established Pharmaceuticals
Robert Funck, Chief Financial Officer, Executive Vice President - Finance
Daniel Salvadori, Senior Vice President - Established Pharmaceuticals, Latin America.
Andrea Wainer, Executive Vice President - Rapid and Molecular Diagnostics
Melissa Brotz, VP Marketing

Abbott Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Abbott Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Abbott Laboratories

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Abbott Laboratories position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Abbott Laboratories will appreciate offsetting losses from the drop in the long position's value.

Moving together with Abbott Stock

  0.71B1SX34 Boston ScientificPairCorr
The ability to find closely correlated positions to Abbott Laboratories could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Abbott Laboratories when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Abbott Laboratories - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Abbott Laboratories to buy it.
The correlation of Abbott Laboratories is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Abbott Laboratories moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Abbott Laboratories moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Abbott Laboratories can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Abbott Laboratories is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Abbott Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Abbott Laboratories Stock. Highlighted below are key reports to facilitate an investment decision about Abbott Laboratories Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abbott Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
For information on how to trade Abbott Stock refer to our How to Trade Abbott Stock guide.
Note that the Abbott Laboratories information on this page should be used as a complementary analysis to other Abbott Laboratories' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Complementary Tools for Abbott Stock analysis

When running Abbott Laboratories' price analysis, check to measure Abbott Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abbott Laboratories is operating at the current time. Most of Abbott Laboratories' value examination focuses on studying past and present price action to predict the probability of Abbott Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abbott Laboratories' price. Additionally, you may evaluate how the addition of Abbott Laboratories to your portfolios can decrease your overall portfolio volatility.
Stocks Directory
Find actively traded stocks across global markets
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Please note, there is a significant difference between Abbott Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abbott Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abbott Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.